RALEIGH, NC, December 8, 2006 /PRNewswire/ – Micell Technologies announced today that it has appointed David Dresner to serve as the Company’s Chief Financial Officer on an interim basis effective December 16, 2006. Mr. Dresner replaces the Company’s current Chief Financial Officer, Jon Kennedy, who is leaving Micell to assume financial management responsibilities with another Raleigh–based company.

Mr. Dresner, an independent financial consultant, has served as an advisor to Micell over the last year. His background includes 20 years with PricewaterhouseCoopers where he was an Audit Partner.

“We appreciate Jon’s long and valued service to Micell and wish him every success as he pursues this new career opportunity,” said Arthur J. Benvenuto, Chairman and CEO of Micell Technologies. “Dave Dresner’s familiarity with Micell’s operations and strong finance and accounting background will serve us well and we are very pleased that he has agreed to act as the Company’s interim CFO.”

About Micell

Micell Technologies is a privately-held, early-stage biomedical company dedicated to applying its unique surface and polymer modification technologies for improved patient benefits and accelerated product development for medical device and drug delivery applications. The Company’s patented processes and methods for medical device surface modification using supercritical fluids are focused on improvements to current polymer based drug-eluting technologies. To learn more, please visit our website at www.micell.com


Contact: James McClain Ph.D., Chief Technology Officer
Micell Technologies: (919) 313-2111